 JERSEY CITY, N.J., May 11, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vulvovaginal candidiasis VVC, also known as vaginal yeast infection. The New Drug Application NDA for Brexafemme is under review by the U.S. Food and Drug Administration FDA with a Prescription Drug User Fee Act PDUFA action date of June 1, 2021. 